+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lysosomal Storage Disease Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Enzyme Replacement Therapy, Substrate Reduction Therapy), By Disease Type, By Region, And Segment Forecasts, 2025 - 2033

  • PDF Icon

    Report

  • 150 Pages
  • July 2025
  • Region: Global
  • Grand View Research
  • ID: 6154758
Description Jump to:
The global lysosomal storage disease treatment market size was estimated at USD 4.54 billion in 2024 and is projected to reach USD 6.68 billion by 2033, growing at a CAGR of 4.54% from 2025 to 2033, driven by rising diagnostic capabilities, advancements in enzyme replacement and gene therapies, and increased awareness of rare genetic disorders. The lysosomal storage disease (LSD) treatment market is experiencing steady growth due to expanding research and development initiatives and rising awareness about these rare genetic conditions.

Significant R&D investments have enhanced therapeutic advancements, helping address unmet medical needs. A study published by the National Library of Medicine in July 2022 noted that LSDs, as a group, are more prevalent than previously assumed, with a collective incidence ranging from 1 in 5,000 to 1 in 8,000 individuals. It also highlighted the influence of ethnicity and geography on disease prevalence. For instance, Gaucher disease appears in 1 in 40,000 to 60,000 people in the general population, while the rate increases to 1 in 800 among Ashkenazi Jews. Similarly, Tay-Sachs disease and Niemann-Pick A are more common in this demographic, while the Finnish population has a higher frequency of aspartylglucosaminuria at 1 in 18,500. These rising prevalence rates underscore the growing need for effective treatments, fueling market expansion.

The introduction of innovative therapies is expected to strengthen the LSD treatment market further. Companies actively pursue novel drug development, supported by increasing global R&D spending. For example, in February 2021, Genethon initiated a gene therapy clinical trial targeting late-onset Pompe disease in collaboration with Spark Therapeutics, utilizing proprietary technologies. In parallel, awareness campaigns have gained momentum, playing a vital role in improving patient outcomes. In countries like the U.S. and the UK, awareness of Fabry disease has significantly increased through initiatives like Fabry Disease Awareness Month, observed every April, as promoted by the National Fabry Disease Foundation (NFDF), Fabry International Network, Fabry Australia, and the UK’s MPS Society.

Global Lysosomal Storage Disease Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global lysosomal storage disease treatment market report based on treatment type, disease type, and region:

Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Enzyme Replacement Therapy
  • Velaglucerase Alfa
  • Alglucosidase Alfa (Myozyme/Lumizyme)
  • Idursulfase (Elaprase)
  • Imiglucerase (Cerezyme)
  • Others
  • Substrate Reduction Therapy
  • Others

Disease Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Gaucher Disease
  • Mucopolysaccharidoses
  • Pompe Disease
  • Fabry Disease
  • Others

Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment Type
1.2.2. Disease Type
1.2.3. Regional
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Lysosomal Storage Disease (LSDs) Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Lysosomal Storage Disease (LSDs) Treatment Market: Treatment Type Business Analysis
4.1. Treatment Type Market Share, 2025 & 2033
4.2. Treatment Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
4.4. Enzyme Replacement Therapy
4.4.1. Enzyme Replacement Therapy Market, 2021 - 2033 (USD Million)
4.4.2. Velaglucerase Alfa
4.4.2.1. Velaglucerase Alfa Market, 2021 - 2033 (USD Million)
4.4.3. Alglucosidase Alfa (Myozyme/Lumizyme)
4.4.3.1. Alglucosidase Alfa (Myozyme/Lumizyme) Market, 2021 - 2033 (USD Million)
4.4.4. Idursulfase (Elaprase)
4.4.4.1. Idursulfase (Elaprase) Market, 2021 - 2033 (USD Million)
4.4.5. Imiglucerase (Cerezyme)
4.4.5.1. Imiglucerase (Cerezyme) Market, 2021 - 2033 (USD Million)
4.4.6. Others
4.4.6.1. Others Market, 2021 - 2033 (USD Million)
4.5. Substrate Reduction Therapy
4.5.1. Substrate Reduction Therapy Market, 2021 - 2033 (USD Million)
4.5.2. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Lysosomal Storage Disease (LSDs) Treatment Market: Disease Type Business Analysis
5.1. Disease Type Market Share, 2025 & 2033
5.2. Disease Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
5.4. Gaucher Disease
5.4.1. Gaucher Disease Market, 2021 - 2033 (USD Million)
5.5. Mucopolysaccharidoses
5.5.1. Mucopolysaccharidoses Market, 2021 - 2033 (USD Million)
5.6. Pompe Disease
5.6.1. Pompe Disease Market, 2021 - 2033 (USD Million)
5.7. Fabry Disease
5.7.1. Fabry Disease Market, 2021 - 2033 (USD Million)
5.8. Others
5.8.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. Lysosomal Storage Disease (LSDs) Treatment Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2025 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
6.4.1. North America Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Type Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Type Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. U.S. Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Type Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Europe
6.5.1. Europe Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Type Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. Uk Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Type Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Type Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Type Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Type Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Type Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Type Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Type Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Type Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Type Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Type Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Type Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Type Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Type Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Latin America
6.7.1. Latin America Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Type Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Japan Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Type Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. China Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2017 - 2033 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Type Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Type Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Type Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Type Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Pfizer Inc
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Treatment Type Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Takeda Pharmaceutical Company Limited (Shire Plc)
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Treatment Type Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Sanofi (Genzyme Corporation)
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Treatment Type Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. BioMarin
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Treatment Type Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Johnson & Johnson (Actelion Pharmaceuticals Ltd)
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Treatment Type Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Amicus Therapeutics, Inc
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Treatment Type Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Alexion Pharmaceuticals, Inc
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Treatment Type Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Sigilon Therapeutics, Inc
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Treatment Type Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Orphazyme A/S
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Treatment Type Benchmarking
7.5.9.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global lysosomal storage disease (LSDs) treatment market, by region, 2021 - 2033 (USD Million)
Table 4 Global lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 5 Global lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 6 North America lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
Table 7 North America lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 8 North America lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 9 U.S. lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 10 U.S. lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 11 Canada lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 12 Canada lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 13 Mexico lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 14 Mexico lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 15 Europe lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
Table 16 Europe lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 17 Europe lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 18 UK lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 19 UK lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 20 Germany lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 21 Germany lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 22 France lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 23 France lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 24 Italy lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 25 Italy lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 26 Spain lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 27 Spain lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 28 Norway lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 29 Norway lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 30 Denmark lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 31 Denmark lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 32 Sweden lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 33 Sweden lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 34 Asia Pacific lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
Table 35 Asia Pacific lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 36 Asia Pacific lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 37 Japan lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 38 Japan lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 39 China lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 40 China lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 41 India lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 42 India lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 43 Australia lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 44 Australia lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 45 South Korea lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 46 South Korea lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 47 Thailand lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 48 Thailand lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 49 Latin America lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
Table 50 Latin America lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 51 Latin America lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 52 Brazil lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 53 Brazil lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 54 Argentina lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 55 Argentina lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 56 Middle East & Africa Lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
Table 57 Middle East & Africa lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 58 Middle East & Africa lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 59 South Africa lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 60 South Africa lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 61 Saudi Arabia lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 62 Saudi Arabia lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 63 UAE lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 64 UAE lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
Table 65 Kuwait lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
Table 66 Kuwait lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Lysosomal storage disease (LSDs) treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and disease type outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Lysosomal storage disease (LSDs) treatment market dynamics
Fig. 12 Lysosomal storage disease (LSDs) treatment market: Porter’s five forces analysis
Fig. 13 Lysosomal storage disease (LSDs) treatment market: PESTLE analysis
Fig. 14 Treatment Type market, 2021 - 2033 (USD Million)
Fig. 15 Enzyme Replacement Therapy market, 2021 - 2033 (USD Million)
Fig. 16 Velaglucerase Alfa market, 2021 - 2033 (USD Million)
Fig. 17 Alglucosidase Alfa (Myozyme/Lumizyme) market, 2021 - 2033 (USD Million)
Fig. 18 Idursulfase (Elaprase) market, 2021 - 2033 (USD Million)
Fig. 19 Imiglucerase (Cerezyme) market, 2021 - 2033 (USD Million)
Fig. 20 Others market, 2021 - 2033 (USD Million)
Fig. 21 Substrate reduction therapy market, 2021 - 2033 (USD Million)
Fig. 22 Others market, 2021 - 2033 (USD Million)
Fig. 23 Disease Type market, 2021 - 2033 (USD Million)
Fig. 24 Gaucher disease market, 2021 - 2033 (USD Million)
Fig. 25 Mucopolysaccharidoses market, 2021 - 2033 (USD Million)
Fig. 26 Pompe disease market, 2021 - 2033 (USD Million)
Fig. 27 Fabry disease market, 2021 - 2033 (USD Million)
Fig. 28 Others market, 2021 - 2033 (USD Million)
Fig. 29 Lysosomal storage disease (LSDs) treatment market revenue, by region
Fig. 30 Regional marketplace: Key takeaways
Fig. 31 North America lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 32 U.S. country dynamics
Fig. 33 U.S. lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 34 Canada country dynamics
Fig. 35 Canada lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 36 Mexico country dynamics
Fig. 37 Mexico lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 38 Europe lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 39 UK country dynamics
Fig. 40 UK lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 41 Germany country dynamics
Fig. 42 Germany lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 43 France country dynamics
Fig. 44 France lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 45 Italy country dynamics
Fig. 46 Italy lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 47 Spain country dynamics
Fig. 48 Spain lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 49 Norway country dynamics
Fig. 50 Norway lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 51 Sweden country dynamics
Fig. 52 Sweden lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 53 Denmark country dynamics
Fig. 54 Denmark lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 55 Asia Pacific lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 56 Japan country dynamics
Fig. 57 Japan lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 58 China country dynamics
Fig. 59 China lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 60 India country dynamics
Fig. 61 India lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 62 Australia country dynamics
Fig. 63 Australia lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 64 South Korea country dynamics
Fig. 65 South Korea lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 66 Thailand country dynamics
Fig. 67 Thailand lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 68 Latin America lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 69 Brazil country dynamics
Fig. 70 Brazil lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 71 Argentina country dynamics
Fig. 72 Argentina lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 73 MEA lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 74 South Africa country dynamics
Fig. 75 South Africa lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 76 Saudi Arabia country dynamics
Fig. 77 Saudi Arabia lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 78 UAE country dynamics
Fig. 79 UAE lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 80 Kuwait country dynamics
Fig. 81 Kuwait lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
Fig. 82 Company categorization
Fig. 83 Company market position analysis
Fig. 84 Strategic framework

Companies Mentioned

  • Pfizer Inc
  • Takeda Pharmaceutical Company Limited (Shire Plc)
  • Sanofi (Genzyme Corporation)
  • BioMarin
  • Johnson & Johnson (Actelion Pharmaceuticals Ltd)
  • Amicus Therapeutics, Inc
  • Alexion Pharmaceuticals, Inc
  • Sigilon Therapeutics, Inc
  • Orphazyme A/S

Related Topics

Related Reports

U.S. Lysosomal Storage Disease Treatment Market Size, Share & Trends Analysis Report By Type (Enzyme Replacement Therapy (ERT)), By Disease Type, By Country, And Segment Forecasts, 2025 - 2033 - Product Image

U.S. Lysosomal Storage Disease Treatment Market Size, Share & Trends Analysis Report By Type (Enzyme Replacement Therapy (ERT)), By Disease Type, By Country, And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • United States
From
Lysosomal Storage Diseases Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Lysosomal Storage Diseases Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Lysosomal Storage Diseases - Global Strategic Business Report - Product Image

Lysosomal Storage Diseases - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Lysosomal Disease Treatment Market Size, Share & Industry Trends Analysis Report By Disease Type (Gaucher's Diseases, Fabry Diseases, Mucopolysaccharidosis, Pompe's Syndrome), By Type of Therapy By End User, By Regional Outlook and Forecast, 2022 - 2028 - Product Image

Lysosomal Disease Treatment Market Size, Share & Industry Trends Analysis Report By Disease Type (Gaucher's Diseases, Fabry Diseases, Mucopolysaccharidosis, Pompe's Syndrome), By Type of Therapy By End User, By Regional Outlook and Forecast, 2022 - 2028

  • Report
  • 230 Pages
  • Global
From
Lysosomal Disease Treatment - Global Strategic Business Report - Product Image

Lysosomal Disease Treatment - Global Strategic Business Report

  • Report
  • 477 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.